Arcascope, a circadian rhythms technology company, recently announced that the organization raised $2.85 million to accelerate the commercial rollout of its evidence-based offering for shift workers and their employers while expanding into new application areas.
According to a statement from the company, the closing of a $2.85 million seed round was led by Supermoon Capital, with participation from Inception Health, New Dominion Angels, AIoT Health, Inflect Health, the Accelerate Blue Fund and the Monroe Brown Seed Fund, HealthX Ventures, and other well-respected angel investors.
The company is launching its validated circadian management platform, currently accessible through the smartphone app, Shift, which addresses the pressing unmet needs of shift workers. Working nights causes profound disruption of the body’s internal circadian clock, which has been linked to increased risk of cardiovascular disease, metabolic syndrome, and cancer. Clinical research, spearheaded by the Arcascope team, has shown that tracking this disruption in real-world contexts and making personalized behavioral interventions can improve health.
“Circadian science is in a renaissance, and Arcascope is leading the way in the development of technologies to optimize our temporal health,” says Daniel Forger, a professor of mathematics and professor of computational medicine & bioinformatics at the University of Michigan and the company’s CSO, in a statement.